Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 inpatient dose-ranging study of LY2140023 in schizophrenia
2007-000800-34Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, double-blind trial of pomaglumetad methionil in schizophrenia (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: PANSS total score at 4 weeks, PANSS positive subscale and 6 more. Started May 2007; status: completed.
02
Drugs
pomaglumetad methionil
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2007-000800-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000800-34.